We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Aortech International Plc | LSE:AOR | London | Ordinary Share | GB0033360586 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 126.50 | 123.00 | 130.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMRUA
RUA Life Sciences PLC
22 December 2022
22 December 2022
RNS REACH
RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")
Science Journal Publication
RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the patented long-term implantable biostable polymer, Elast-EonTM, is pleased to announce that further to a presentation at EACTS in 2021 a detailed paper has now been accepted for publication in the Journal of Surgical Research discussing the RUA large bore graft and its similar safety and performance to the control devices. The paper, titled "A Large-Diameter Vascular Graft Replacing Animal-Derived Sealants with an Elastomeric Polymer", can be read on Science Direct by following the link below:
www.sciencedirect.com/science/article/pii/S002248042200782X
A copy of the paper will also be available on the RUA Life Sciences website.
Bill Brown, Chairman of RUA Life Sciences quoted:
"I would like to thank the team at Leuven for the preparation of this paper. No surprises came out of the study and I am delighted that the RUA graft behaved well in surgical handling and overall outcome with the ElastEon sealant performing as expected with no indications of the adhesions."
For more information please contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0)1294 317073
Dr Caroline Stretton, Group MD Tel: +44 (0)1294 317073
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAFLFESFFLLFIF
(END) Dow Jones Newswires
December 22, 2022 02:00 ET (07:00 GMT)
1 Year Aortech Chart |
1 Month Aortech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
